KLINIK HOLAT: INTERSTITSIAL O‘PKA KASALLIGI VA IJOBIY DIASKINTEST; DIAGNOSTIKA STANDARTLARI, MSKT VA DAVOLASH TAKTIKASI (FARG‘ONA VFPM TAJRIBASI)
Keywords:
interstitsial o‘pka kasalligi, NSIP, Diaskintest, latent sil infeksiyasi, MSKT (HRCT), imunosupressiya, Farg‘ona.Abstract
Ushbu maqolada interstitsial o‘pka kasalligi (IÖK; NSIP fenotipi) bo‘lgan bemorda Diaskintest ijobiy chiqqan holat, aktiv silni bosqichma-bosqich istisno qilish, latent sil infeksiyasi (LSI)ni tasdiqlash va imunosupressiv davoga tayyorgarlik jarayonida LSIni oldini olish (profilaktika)ning amaliy algoritmi bayon qilinadi. MSKT–yuqori aniqlikdagi protokol, ATS/ERS standartlari asosidagi diagnostika yondashuvi va Farg‘ona viloyat ftiziatriya va pulmonologiya markazi (VOFPM) amaliyotidan olingan hujjat ma’lumotlari integratsiya qilingan.
References
1. Raghu G, Remy Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198(5):e44–e68. doi:10.1164/rccm.201807-1255ST.
2. Raghu G, Remy Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (An Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18–e47. doi:10.1164/rccm.202202-0399ST.
3. Raghu G, Wilson KC, et al. Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;202(3):e36–e69. doi:10.1164/rccm.202005-2032ST.
4. Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society white paper. Lancet Respir Med. 2018;6(2):138–153.
5. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Remy J. Fleischner Society: Glossary of Terms for Thoracic Imaging. Radiology. 2008;246(3):697–722. doi:10.1148/radiol.2462070712.
6. World Health Organization. Consolidated guidelines on tuberculosis: Module 1: Prevention – Tuberculosis preventive treatment. Geneva: WHO; 2020. Available at: https://www.who.int/publications
7. Sterling TR, Njie G, Zenner D, et al. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020;69(1):1–11. doi:10.15585/mmwr.rr6901a1.
8. Maher TM, Lancaster LH, Jouneau S, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases (INBUILD). N Engl J Med. 2019;381:1718–1727. doi:10.1056/NEJMoa1908681.
9. Generium JSC. Instruktsiya po meditsinskomu primeneniyu: rekombinant tuberkulyoz allergeni ESAT 6/CFP 10 (Diaskintest). (Rossiya Federatsiyasi davlat ro‘yxati, ishlab chiqaruvchi: OOO “Generium”). Oxirgi tahrir – rasmiy yo‘riqnoma.
10. Farg‘ona viloyat ftiziatriya va pulmonologiya markazi. Chiqish epikrizi (DMED Yagona tibbiy axborot tizimi), hujjat ID: a7c0ecec 4c20 423a a4cb 16d89a67730e; yaratilgan sana: 30.06.2025.
11. Cottin V, Hirani NA, Hotchkin DL, et al. Presentation, diagnosis and clinical course of the progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150):180076. doi:10.1183/16000617.0076-2018.
12. Brown KK, Martinez FJ, Walsh SLF, et al. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J. 2020;55(6):2000085. doi:10.1183/13993003.00085-2020.
